Shamburg News · 8-K filed Nov 16, 2026, 8:30 AM EST
Arcturus Therapeutics Sells $50 Million of Common Stock to Meiji Seika Pharma in Private Placement
ARCT · Arcturus Therapeutics Holdings Inc.
- Material agreement
- Financing
- Reg FD disclosure
- Materiality: high
On November 16, 2026, Arcturus Therapeutics Holdings Inc. sold 2,466,395 shares of common stock to Meiji Seika Pharma Co., Ltd. for an aggregate purchase price of $50.0 million, at a premium of 80% to the 30-day average closing price. The company also granted Meiji a registration rights agreement and entered into an exclusive license for ARCT-154 technology and a non-binding MOU on a pandemic preparedness program in Japan. If a definitive license is not signed by May 31, 2027, the company must refund 50% of the premium, approximately $11.1 million.
Source: SEC EDGAR, Form 8-K, Items 1.01, 3.02, 7.01, 9.01, accession 0001193805-26-001485.
Written from the filing by Shamburg Markets. Figures are as reported by the company.